http://www.nature.com/neuro/journal/v5/n11s/full/nn936.html
Since the mid 1980s, there has been a
great deal of enthusiasm within both academia and industry about the
therapeutic potential of drugs targeting the NMDA subtype of glutamate
receptors. That early promise is just beginning to translate into
approvable drugs. Here we review the reasons for this slow progress and
critically assess the future prospects for drugs that act on NMDA
receptor pathways, including potential treatments for some major
disorders such as stroke and Alzheimer's disease, for which effective
therapies are still lacking.
To read this story in full you will need to login or make a payment (see right).
No comments:
Post a Comment